drugset / Trial / NCT04362410
Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a Phase 1, Single Centre, Double-blind, Randomized, Placebo-controlled Parallel-group Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Tezepelumab after Single-Dose Subcutaneous Administration in Healthy Chinese Subjects.
Timeline
- Start
- 2020-05-18
- Primary completion
- 2020-10-09
- Completion
- 2020-10-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tezepelumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.